Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorinde M van Andel

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|January 15, 2021
Dr. Sprengers et al. ReplyJan J Sprengers, Dorinde M van Andel, Hilgo Bruining
Journal of Autism and Developmental Disorders|January 10, 2023
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled TrialDorinde M van Andel, Jan J Sprengers, Marsh Königs, et al.
Molecular Autism|May 9, 2020
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyDorinde M van Andel, Jan J Sprengers, Bob Oranje, et al.
Journal of Patient-Reported Outcomes|November 17, 2021
The sensory-reactivity PROM set: identification of a parent reported outcome measure set for autism spectrum disorderDorinde M van Andel, Henk F van Stel, Floortje E Scheepers, et al.
The International Journal of Eating Disorders|May 18, 2026
Validation of the ED-15-NL, a Brief Session-by-Session Questionnaire to Measure Changes in Eating Disorder Cognitions and BehaviorsCaya H van Eikenhorst, Benny van der Vijgh, Sanne F W Marcic-van Doornik, et al.
Frontiers in Psychiatry|February 25, 2022
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled TrialDorinde M van Andel, Jan J Sprengers, Mandy G Keijzer-Veen, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 31, 2020
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority TrialJan J Sprengers, Dorinde M van Andel, Nicolaas P A Zuithoff, et al.
Frontiers in Neuroscience|June 1, 2022
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label StudyErika L Juarez-Martinez, Dorinde M van Andel, Jan J Sprengers, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|September 10, 2021
Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum DisorderErika L Juarez-Martinez, Jan J Sprengers, Gianina Cristian, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of the American Academy of Child and Adolescent Psychiatry|January 15, 2021
Dr. Sprengers et al. ReplyJan J Sprengers, Dorinde M van Andel, Hilgo Bruining
Journal of Autism and Developmental Disorders|January 10, 2023
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled TrialDorinde M van Andel, Jan J Sprengers, Marsh Königs, et al.
Molecular Autism|May 9, 2020
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyDorinde M van Andel, Jan J Sprengers, Bob Oranje, et al.
Journal of Patient-Reported Outcomes|November 17, 2021
The sensory-reactivity PROM set: identification of a parent reported outcome measure set for autism spectrum disorderDorinde M van Andel, Henk F van Stel, Floortje E Scheepers, et al.
The International Journal of Eating Disorders|May 18, 2026
Validation of the ED-15-NL, a Brief Session-by-Session Questionnaire to Measure Changes in Eating Disorder Cognitions and BehaviorsCaya H van Eikenhorst, Benny van der Vijgh, Sanne F W Marcic-van Doornik, et al.
Frontiers in Psychiatry|February 25, 2022
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled TrialDorinde M van Andel, Jan J Sprengers, Mandy G Keijzer-Veen, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 31, 2020
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority TrialJan J Sprengers, Dorinde M van Andel, Nicolaas P A Zuithoff, et al.
Frontiers in Neuroscience|June 1, 2022
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label StudyErika L Juarez-Martinez, Dorinde M van Andel, Jan J Sprengers, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|September 10, 2021
Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum DisorderErika L Juarez-Martinez, Jan J Sprengers, Gianina Cristian, et al.
Pageof 1